The primary source of cardiac safety concern, particularly for infliximab, stems from the ATTACH (Anti-TNF Therapy Against Congestive Heart Failure) trial, a placebo-controlled RCT involving non-IBD patients with moderate-to-severe HF [26]. Here, TNF is linked to hydrops fetalis.